Literature DB >> 35145198

Atypical thymomas with squamoid and spindle cell features: clinicopathologic, immunohistochemical and molecular genetic study of 120 cases with long-term follow-up.

David I Suster1,2, A Craig Mackinnon3, Marcello DiStasio4, Malay Kumar Basu3, German Pihan1, Saul Suster5.   

Abstract

Thymomas are rare tumors characterized by a broad range of morphologic appearances that can sometimes give rise to difficulties for classification. We have studied a series of 120 thymoma patients in whom the tumors were characterized by sheets of atypical epithelial cells with squamoid and/or spindle cell features. They occurred in 63 men and 57 women and presented as a discrete mass in the anterior mediastinum measuring 2-23 cm (mean: 8.2 cm). Patients' ages ranged from 14 to 86 years (mean: 57.8) and most had symptoms referable to a mass lesion. 20 patients had myasthenia gravis or other autoimmune disorder. 76 cases were characterized by a predominant population of round to polygonal tumor cells while 32 cases were characterized by atypical oval or spindle cells. 12 cases showed mixed features and 16 cases showed the development of thymic carcinoma arising from thymoma. All cases were positive for p40/p63 and cytokeratin AE1/AE3. 23 cases were positive for CD5 (25%), and 13 for CD117 (14%). MIB1 showed a significant increase in proliferative activity (mean = 11.6%). Next generation sequencing in 47 cases did not disclose any variants amenable to current targeted therapies. Clinical follow up ranging from 2 to 29 years showed a progressive increase in aggressive behavior and fatality rate with advancing stage. Overall survival was 87% at 5 years, 67% at 10 years, and 23% at 20 years. Completeness of resection and staging were the most significant parameters for survival. The more aggressive tumors followed a protracted clinical course with multiple recurrences and metastases over a long period of time (mean = 19.8 years from time of initial relapse to death). Atypical thymomas are a distinct category of thymic epithelial neoplasm characterized by a slowly progressive clinical course with increased potential for metastases, transformation to a higher-grade malignancy, and fatal outcome in some cases.
© 2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Year:  2022        PMID: 35145198     DOI: 10.1038/s41379-022-01013-x

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   8.209


  36 in total

1.  Thymoma: a clinicopathologic study.

Authors:  P E BERNATZ; E G HARRISON; O T CLAGETT
Journal:  J Thorac Cardiovasc Surg       Date:  1961-10       Impact factor: 5.209

2.  The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.

Authors:  Atsushi Hayashi; Takumi Fumon; Yukari Miki; Hiaki Sato; Tadashi Yoshino; Kiyoshi Takahashi
Journal:  J Clin Exp Hematop       Date:  2013

3.  MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Authors:  Kyoichi Kaira; Haruyasu Murakami; Masakuni Serizawa; Yasuhiro Koh; Masato Abe; Yasuhisa Ohde; Toshiaki Takahashi; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Virchows Arch       Date:  2011-01-21       Impact factor: 4.064

4.  Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.

Authors:  Xue-Ying Su; Wei-Ya Wang; Jin-Nan Li; Dian-Ying Liao; Wei-Lu Wu; Gan-Di Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China.

Authors:  Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

7.  A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma.

Authors:  K Koga; Y Matsuno; M Noguchi; K Mukai; H Asamura; T Goya; Y Shimosato
Journal:  Pathol Int       Date:  1994-05       Impact factor: 2.534

8.  Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.

Authors:  Masakazu Kojika; Genichiro Ishii; Junji Yoshida; Mituyo Nishimura; Tomoyuki Hishida; Shu-ji Ota; Yukinori Murata; Kanji Nagai; Atsushi Ochiai
Journal:  Mod Pathol       Date:  2009-07-31       Impact factor: 7.842

9.  ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.

Authors:  Alexander Marx; Philipp Ströbel; Sunil S Badve; Lara Chalabreysse; John K C Chan; Gang Chen; Laurence de Leval; Frank Detterbeck; Nicolas Girard; Jim Huang; Michael O Kurrer; Libero Lauriola; Mirella Marino; Yoshihiro Matsuno; Thierry Jo Molina; Kiyoshi Mukai; Andrew G Nicholson; Daisuke Nonaka; Ralf Rieker; Juan Rosai; Enrico Ruffini; William D Travis
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

10.  CADD: predicting the deleteriousness of variants throughout the human genome.

Authors:  Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.